Bispecific antibodies (bsAbs) present significantly greater manufacturing and developability challenges than conventional monoclonal antibodies. Since bsAbs require the coordinated assembly of multiple polypeptide chains, production must ensure correct heavy chain–heavy chain (HC-HC) and heavy chain–light chain (HC-LC) pairing while minimizing unwanted molecular species. Developers must also preserve critical quality attributes (CQAs), such as target-binding affinity, molecular stability, pharmacokinetics, and therapeutic efficacy. Even minor assembly errors can generate heterogeneous product populations with physicochemical properties that closely resemble those of the desired bsAb, making detection and removal difficult during downstream processing. Chain mispairing introduces development risks, including reduced yields, increased purification complexity, and challenges in maintaining consistent product quality. Balancing manufacturability with CQAs remains a central challenge in bsAb development.
To address these obstacles, next-generation engineering platforms are focusing on the molecular design stage to improve assembly fidelity. Samsung Biologics’ S-DUAL® platform uses a differentiated asymmetric antibody architecture and an S-KiH (knob-into-hole) Fc engineering strategy to promote selective heterodimer formation and reduce chain mispairing. By promoting correct chain assembly upstream, the platform simplifies downstream purification, increases product purity, and enhances manufacturing robustness.
Features and Benefits
A key feature of the S-DUAL® approach is that it preserves native antigen-binding regions without requiring engineering of the complementarity-determining regions (CDRs). This retains parental antibody binding while enabling modular adaptation across target combinations. The platform supports scalability from early discovery through manufacturing, enabling drug developers to assess therapeutic performance and developability in a unified workflow.
As the industry expands beyond conventional monoclonal antibodies toward multispecific formats, success will depend on therapeutic efficacy and manufacturability. The S-DUAL® platform addresses both needs by integrating developability considerations directly into the molecular design.
Applications
During molecular assembly, competing chain-pairing interactions can generate heterogeneous product populations. Heterogeneity reduces yield, complicates purification, and introduces development risks. As a result, bsAb engineering has increasingly focused on designing molecules that favor correct assembly at the outset rather than relying on downstream purification to remove undesirable variants.
The S-DUAL® platform operates on this principle. Its asymmetric antibody architecture promotes preferential pairing between intended chains while reducing incorrect HC-LC associations. By biasing assembly toward the desired configuration, the platform improves product homogeneity at the earliest stages of molecule formation. This design directly mitigates the persistent challenge of mispaired species, which are difficult to separate using conventional methods. This architecture is complemented by the S-KiH engineering strategy, which enhances heavy-chain heterodimerization through Fc-region engineering. Traditional knob-into-hole approaches promote heterodimer formation, but Fc engineering alone does not fully eliminate mispairing elsewhere in the molecule. The S-KiH approach strengthens heterodimer specificity within a broader design framework, minimizing mispairing across multiple assembly pathways simultaneously. Biophysical characterization of S-DUAL® demonstrated high purity, strong expression yields, and favorable stability. Importantly, these developability improvements do not compromise biological function. Functional studies have demonstrated that target binding, signaling inhibition, and antitumor activity are comparable to or exceed those of reference antibodies.
In vivo, S-DUAL® achieved significant tumor growth inhibition; low-dose activity matched the efficacy of higher-dose reference antibody, indicating superior potency.
These advantages translate into:
- High yield of 8 g/L, and purity of >99% supporting scalable manufacturing
- Robust stability that reduces downstream processing challenges and formulation risks
- Improved in vivo potency that may enable lower dosing
- Reduced development risk through early validation
From a development perspective, improved assembly at the design stage reduces the downstream purification burden, simplifies analytics, and enhances manufacturing consistency. As bsAb formats grow more complex, integrated platforms that combine assembly control with developability considerations will play an important role in scalable therapeutic development.